Japanthanks.com August 8, Olympics Closing Ceremony - Why Bach Can't lose by announcing suspension of summer olympics until covid slayed

Thursday, October 5, 2017

Guadalajara, Mexico | 11 – 14 October 2017
MSF EVENTS

endTB Symposium: Accelerating TB elimination through access to bedaquiline and delamanid Hall 10 - Jalisco Hall October 12 14:00 – 15:30
The symposium will provide an update on the UNITAID-funded endTB initiative and findings, including culture conversion and reversion and adverse events for the 600 people who have received bedaquiline or delamanid.
Community space (Encuentro) session: Five urgent improvements to DR-TB treatment Foro - Encuentro Expo October 13 17:00 – 18:00
Evidence for treatment with newer DR-TB drugs, shorter treatment regimens, ambulatory care instead of hospitisation, and fast-track registration of new drugs.
MSF Symposium: Reducing catastrophic costs for people with TB through patient-centred care Hall 10 - Jalisco Hall October 14 10:30 – 12:00
Session will analyse the barriers to reducing costs and burden for people with drug-resistant TB including: decentralised and ambulatory treater, shorter treatment and newer drugs to reduce toxicity, and interventions to reduce out-of-pocket costs of treatment.
ORAL ABSTRACTS

TB POLICIES
Many national TB programmes are out of step with international recommendations for testing, treatment and prevention: results of a 30 country survey Hall 2 – Events Ballroom October 12 16:00 – 17:30 SOA-365-12
Setting up an active pharmacovigilance system for the endTB project Hall 13 - Jalisco Hall October 13 10:30 – 12:00 OA-160-13
DRUG-RESISTANT TB TREATMENT
Early safety and efficacy of bedaquiline and delamanid combination for drug-resistant TB in Armenia, India and South Africa Plenary Hall October 13 10:30-12:00 OA-2905-13
Adverse events over 6 months with delamanid in a programmatic setting in Khayelitsha, South Africa Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-162-13
Safety of multidrug resistant tuberculosis treatment amongst patients receiving bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-163-13
Risk factors for developing hypothyroidism among MDR-TB patients receiving Eto and/or PAS in Maputo, Mozambique Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-164-13
Psychiatric comorbidity among drug-resistant tuberculosis patients Hall 13 – Jalisco Hall October 13 10:30 – 12:00 OA-167-13
Culture conversion and reversion of multidrug resistant tuberculosis patients receiving bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-188-13
Bedaquiline- and linezolid-based regimens for fluoroquinolone-resistant MDR-TB: how much better is it? Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-190-13
Outcomes of multidrug resistant tuberculosis patients receiving Bedaquiline in a compassionate use program in Armenia and Georgia Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-192-13
Delamanid for rifampicin-resistant tuberculosis: an observational cohort study from Khayelitsha, South Africa Hall 13 – Jalisco Hall October 13 16:00 – 17:30 OA-193-13
TB DIAGNOSTICS
Value of determine-TB LAM test as screening test and as diagnostic tool for tuberculosis diagnosis in HIV positive adults Hall 8 – Events Ballroom October 13 10:30 – 12:00 SOA-402-13
Cost-effectiveness of including determine TB-LAM test to diagnose tuberculosis in HIV-positive symptomatic patients Hall 4 – Events Ballroom October 14 10:30 – 12:00 SOA-443-14
LATENT TB INFECTION
Incidence of latent tuberculosis infection and tuberculosis disease after 24 months follow-up in paediatric contacts of drug-resistant tuberculosis patients in Armenia Hall 13 - Jalisco Hall October 12 14:00 – 15:30 SOA-360-12
CO-INFECTIONS (HCV)
High rates of active hepatitis C amongst multidrug resistant tuberculosis patients in Armenia Hall 14 - Jalisco Hall October 12 10:30 – 12:00 OA-125-12
POSTER PRESENTATIONS
All poster prentations take place in the Poster Area from 12:45 – 13:45 on the designated date

TB POLICIES
Threats to affordable quality second-line TB drugs in Eastern Europe/Central Asia as the Global Fund shifts to national procurement October 14 PD-893-14
DRUG-RESISTANT TB TREATMENT
Introduction of a short standardized course of treatment for multidrug-resistant Tuberculosis in Mozambique: cohort description and early culture conversion in HIV-positive and HIV-negative patients October 12 PD-537-12
Outcomes and risk factors in a program treating MDR-TB in Swaziland for 2011-2013 cohorts October 12 PD-547-12
Drug induced hypothyroidism during treatment for multidrug resistant tuberculosis in Swaziland October 13 PD-685-13
Lessons learned from the design, development, and deployment of endTB electronic medical record for MDR-TB across 16 countries October 13 PD-700-13
Interim report on the use of a short, simplified regimen for the treatment of children with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan October 13 PD-809-13
Accelerating access to delamanid for rifampicin-resistant tuberculosis in Khayelitsha, South Africa October 14 PD-891-14
The impact of pyrazinamide resistance upon the treatment outcome of patients with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan October 14 PD-894-14
TB DIAGNOSTICS
Evaluation of the OMNIgene® SPUTUM reagent for long term transportation of samples for Xpert testing in a high TB-HIV setting October 13 PD-837-13
Does the determine-TB LAM test have a potential value in tuberculosis diagnosis among severely acute malnourished (SAM) children? October 14 PD-924-14
LATENT TB INFECTION
Discordances between TST and IGRA to detect latent tuberculosis infection in paediatric contacts of drug-resistant tuberculosis patients October 14 PD-944-14
REPORTS
For MSF TB reports, go to: https://www.msfaccess.org/tb
· Out of Step 2017: www.msfaccess.org/outofstep2017
· DR-TB Drugs Under the Microscope, 5th Edition (COMING SOON)

No comments:

Post a Comment